Latest / Research To Practice | Oncology Videos
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Featuring an interview with Dr Erika Hamilton, including the following topics:
General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11)
Mechanisms of resistance to endocrine therapy (10:08)
Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26)
Other applications for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.